total energy Table Glycemic index and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR dose-response analysis Cases/ Author, Year, Study name, size Case Exposure RR (95%CI) Adjustment Reasons for WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors exclusion Country 1 096/ Incidence, colorectal 1.08 (0.87-1.34) 130 719 81 vs 65 cancer, women Ptrend:0.27 20 years Incidence, colon 1.06 (0.83-1.36) 858/ 81 vs 65 cancer, women Ptrend:0.29 Self-report, Incidence, colorectal 1.14 (0.88-1.48) medical record 683/ 82 vs 69 NHS-HPFS, cancer, men Ptrend:0.33 Michaud, 2005 and pathology Prospective COL01824 report reviewed FFQ Incidence, colon 1.13 (0.84-1.51) Cohort, 552/ 82 vs 69 USA by centrally cancer, men Ptrend:0.40 M/W trained physician Incidence, proximal 1.11 (0.77-1.58) 403/ colon cancer, 81 vs 65 Ptrend:0.27 women Incidence, distal 0.91 (0.63-1.34) 326/ colon cancer, 81 vs 65 Ptrend:0.82 women
total energy Table Glycemic index and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR dose-response Author, Year, WCRF Code, Country Study name, characteristics Cases/ size Follow-up Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Reasons for exclusion Michaud, 2005 COL01824 USA NHS-HPFS, Prospective Cohort, M/W 1 096/ 130 719 20 years Self-report, medical record and pathology report reviewed by centrally trained physician FFQ Incidence, colorectal cancer, women 81 vs 65 1.08 (0.87-1.34) Ptrend:0.27 858/ Incidence, colon cancer, women 81 vs 65 1.06 (0.83-1.36) Ptrend:0.29 683/ Incidence, colorectal cancer, men 82 vs 69 1.14 (0.88-1.48) Ptrend:0.33 552/ Incidence, colon cancer, men 82 vs 69 1.13 (0.84-1.51) Ptrend:0.40 403/ Incidence, proximal colon cancer, women 81 vs 65 1.11 (0.77-1.58) Ptrend:0.27 326/ Incidence, distal colon cancer, women 81 vs 65 0.91 (0.63-1.34) Ptrend:0.82 analysis
CUP_colorectal_SLR_2016_RO.docx